Shortly after announcing Chinese approval for its novel small molecule roxadustat, AstraZeneca (LSE: AZN) has revealed positive Phase III data for the therapy, which is being developed to treat anemia in people with chronic kidney disease (CKD).
The drug is a new first-in-class treatment for the condition, which the London-listed firm is developing in collaboration with US company FibroGen (Nasdaq: FGEN).
Data from the trials will be part of the regulatory submission package in the USA and other major countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze